Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Industry

5 Apr 2023

Beckley Psytech Launches Phase 2a study of 5-MeO-DMT for Alcohol Use Disorder

Beckley Psytech is moving its 5-MeO-DMT program forward, announcing a new Phase IIa study investigating its lead candidate, BPL-003, as a potential treatment for alcohol use disorder (AUD)....

By Microdose NewsDesk

Industry

5 Apr 2023

MAPS Announces Positive Topline Results from Follow-Up Study

More good news from MAPS as it moves its trials through the final approval steps....

By Microdose NewsDesk

Law & Politics

4 Apr 2023

Republican Lawmaker Introduces Bills to Legalize Psychedelics and Plant Medicines

Massachusetts State Representative Nicholas Boldyga (R-Southwick), widely regarded as the most conservative member of the Massachusetts legislature, recently announced the filing of legislation that would legalize certain psychedelic compounds and...

By Microdose NewsDesk

Finance

4 Apr 2023

Enveric Biosciences Reports Q4 and Year-End 2022 Results

Enveric Biosciences, Inc....

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

29 Mar 2023

PharmaTher Announces Positive FDA Meeting; Path Towards Phase 3 Trial

PharmaTher continues to move its niche ketamine programs through the FDA process....

By Microdose NewsDesk

Industry

29 Mar 2023

Atai CEO Answers Questions From the Public

Reddit is the internet incarnate....

By Microdose NewsDesk

Law & Politics

28 Mar 2023

Massachusetts Bill Would Cap MDMA Therapy Costs at $5,000

This is the language used in bill HD2137, filed by Massachusetts State Representative. Nick Boldyga, a Republican, has proposed a bill that would not only re-schedule MDMA automatically upon FDA...

By Microdose NewsDesk

Don’t Miss

27 Mar 2023

News You Might Have Missed: March 27th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Law & Politics

24 Mar 2023

Oregon Issues US’s First Psilocybin License

Oregon Health Authority (OHA) has issued the state’s first psilocybin license as part of the nation’s first regulatory framework for psilocybin services....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.